This report provides a summary of the horizon scan carried out to look at the indications for pembrolizumab, atezolizumab, and nivolumab that might get market approval in UK in the next few years. It presents the findings of our analysis regarding number of MInD records for each of the drugs, status of the records on IO’s MInD database, phase of clinical trial development, type of sponsors of the trials, therapy areas of the indications, stage of disease, subgroups, and place in treatment. It briefly goes over how many MInD records had regulatory estimates for the UK, the number of records where clinical trials were investigating the three drugs as histology independent therapy, monotherapy, or combination therapy. The report also includes the methods undertaken to carry out the scan, limitations and challenges experienced during the process, and recommendations for future work.
Horizon Scan for Immuno-Oncology Products: Mapping future indications for Pembrolizumab, Nivolumab and Atezolizumab
Horizon scan of indications for pembrolizumab, atezolizumab, and nivolumab that could potentially get market approval and disrupt clinical pathways in the NHS in England in the near future.